These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 8537676)

  • 21. Combined drugs may be better than zidovudine alone for immunocompromised adults infected with HIV-1.
    Commun Dis Rep CDR Wkly; 1995 Oct; 5(42):209. PubMed ID: 7496435
    [No Abstract]   [Full Text] [Related]  

  • 22. [Anti-retroviral monotherapy with nucleoside analogues].
    de Mendonça JS
    Rev Soc Bras Med Trop; 1995; 28 Suppl 2():5-9. PubMed ID: 8693151
    [No Abstract]   [Full Text] [Related]  

  • 23. Effects of spontaneous gastric hypoacidity on the pharmacokinetics of zidovudine and didanosine.
    Shelton MJ; Adams JM; Hewitt RG; Steinwandel C; DeRemer M; Cousins S; Morse GD
    Pharmacotherapy; 1997; 17(3):438-44. PubMed ID: 9165548
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment options for human immunodeficiency virus.
    Heins JR
    S D J Med; 1996 Feb; 49(2):51-2. PubMed ID: 9122670
    [No Abstract]   [Full Text] [Related]  

  • 25. [Didanosine].
    Enferm Infecc Microbiol Clin; 1995 Oct; 13(8):487-90. PubMed ID: 8555311
    [No Abstract]   [Full Text] [Related]  

  • 26. [Therapy of HIV infection with nucleoside analogs].
    Jablonowski H; Mauss S; Armbrecht C; Manegold C; Szelenyi H; Hengels KJ
    Z Gastroenterol; 1993 Nov; 31 Suppl 5():60-6. PubMed ID: 8197806
    [No Abstract]   [Full Text] [Related]  

  • 27. Effects of a combination of zidovudine, didanosine, and lamivudine on primary human immunodeficiency virus type 1 infection.
    Lafeuillade A; Poggi C; Tamalet C; Profizi N; Tourres C; Costes O
    J Infect Dis; 1997 May; 175(5):1051-5. PubMed ID: 9129065
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized trial (ISS 902) of didanosine versus zidovudine in previously untreated patients with mildly symptomatic human immunodeficiency virus infection.
    Floridia M; Vella S; Seeber AC; Tomino C; Fragola V; Weimer LE; Ricciardulli D; Milazzo F; Gritti FM; Mazzotta F; Ranieri S; Chiodo F; Moroni M; Cargnel A; Bassetti D; Giannini V; Cremoni L; Concia E; Sinicco A; Carosi G; Alberici F; Dianzani F
    J Infect Dis; 1997 Feb; 175(2):255-64. PubMed ID: 9203645
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human immunodeficiency virus type 1 kinetics in lymph nodes compared with plasma.
    Lafeuillade A; Poggi C; Profizi N; Tamalet C; Costes O
    J Infect Dis; 1996 Aug; 174(2):404-7. PubMed ID: 8699075
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Treatment by antiviral drugs of HIV-infected patients].
    Mayaud C
    Rev Pneumol Clin; 1993; 49(2):71-4. PubMed ID: 8272744
    [No Abstract]   [Full Text] [Related]  

  • 31. Antiviral therapy in human immunodeficiency virus infections. Current status (Part I).
    Sandström E; Oberg B
    Drugs; 1993 Apr; 45(4):488-508. PubMed ID: 7684670
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Didanosine. An update on its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV disease.
    Perry CM; Balfour JA
    Drugs; 1996 Dec; 52(6):928-62. PubMed ID: 8957161
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Studies of zidovudine in combination with didanosine and zalcitabine.
    Jablonowski H
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S52-6. PubMed ID: 8595509
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bioavailability of once- and twice-daily regimens of didanosine in human immunodeficiency virus-infected children.
    Abreu T; Plaisance K; Rexroad V; Nogueira S; Oliveira RH; Evangelista LA; Rangel R; Silva IS; Knupp C; Lambert JS
    Antimicrob Agents Chemother; 2000 May; 44(5):1375-6. PubMed ID: 10770783
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection.
    Luzuriaga K; Bryson Y; Krogstad P; Robinson J; Stechenberg B; Lamson M; Cort S; Sullivan JL
    N Engl J Med; 1997 May; 336(19):1343-9. PubMed ID: 9134874
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect on human immunodeficiency virus type 1 RNA levels in cerebrospinal fluid after initiation of zidovudine or didanosine.
    Gisslén M; Norkrans G; Svennerholm B; Hagberg L
    J Infect Dis; 1997 Feb; 175(2):434-7. PubMed ID: 9203666
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human immunodeficiency virus type 1 (HIV-1) viremia changes and development of drug-related mutations in patients with symptomatic HIV-1 infection receiving alternating or simultaneous zidovudine and didanosine therapy.
    Kojima E; Shirasaka T; Anderson BD; Chokekijchai S; Steinberg SM; Broder S; Yarchoan R; Mitsuya H
    J Infect Dis; 1995 May; 171(5):1152-8. PubMed ID: 7751690
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of human immunodeficiency virus type 1 replication in vitro by the bisheteroarylpiperazine atevirdine (U-87201E) in combination with zidovudine or didanosine.
    Campbell TB; Young RK; Eron JJ; D'Aquila RT; Tarpley WG; Kuritzkes DR
    J Infect Dis; 1993 Aug; 168(2):318-26. PubMed ID: 7687641
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Antiviral treatment].
    Hermans P
    Acta Urol Belg; 1993; 61(1-2):593-8. PubMed ID: 7685982
    [No Abstract]   [Full Text] [Related]  

  • 40. Effects of cytokines on antiviral pharmacokinetics: an alternative approach to assessment of drug interactions using bioequivalence guidelines.
    Piscitelli SC; Amatea MA; Vogel S; Bechtel C; Metcalf JA; Kovacs JA
    Antimicrob Agents Chemother; 1996 Jan; 40(1):161-5. PubMed ID: 8787899
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.